Middle East & Africa Carbapenem Market Size & Outlook

The carbapenem market in Middle East & Africa is expected to reach a projected revenue of US$ 183.9 million by 2030. A compound annual growth rate of 5.2% is expected of Middle East & Africa carbapenem market from 2023 to 2030.
Revenue, 2022 (US$M)
$122.3
Forecast, 2030 (US$M)
$183.9
CAGR, 2023 - 2030
5.2%
Report Coverage
Middle East & Africa

MEA carbapenem market highlights

  • The MEA carbapenem market generated a revenue of USD 122.3 million in 2022.
  • The market is expected to grow at a CAGR of 5.2% from 2023 to 2030.
  • In terms of segment, meropenem was the largest revenue generating drug class in 2022.
  • Meropenem is the most lucrative drug class segment registering the fastest growth during the forecast period.
  • Country-wise, South Africa is expected to register the highest CAGR from 2023 to 2030.


MEA data book summary

Market revenue in 2022USD 122.3 million
Market revenue in 2030USD 183.9 million
Growth rate5.2% (CAGR from 2022 to 2030)
Largest segmentMeropenem
Fastest growing segmentMeropenem
Historical data covered2018 - 2021
Base year for estimation2022
Forecast period covered2023 - 2030
Quantitative unitsRevenue in USD million
Market segmentationMeropenem, Imipenem, Ertapenem, Others Drug Class
Key market players worldwideMenarini Group, Pfizer Inc, Sun Pharmaceutical Industries, Lupin, Aurobindo Pharma, Merck & Co Inc, Venus Group


Other key industry trends

  • In terms of revenue, MEA region accounted for 3.4% of the global carbapenem market in 2022.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 1,364.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Carbapenem Market Scope

Carbapenem market segmentation & scope
Meropenem
Imipenem
Ertapenem
Others Drug Class
Urinary Tract Infections
Bloodstream Infections
Intra-abdominal Infections
Pneumonia
Others Application
Hospital Pharmacies
Retail Pharmacies
Others Distribution Channel

Carbapenem Market Companies

Name Profile # Employees HQ Website

Middle East & Africa carbapenem market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to carbapenem market will help companies and investors design strategic landscapes.


Meropenem was the largest segment with a revenue share of 54.78% in 2022. Horizon Databook has segmented the Middle East & Africa carbapenem market based on meropenem, imipenem, ertapenem, others drug class covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Middle East & Africa carbapenem market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Middle East & Africa carbapenem market databook

  • Our clientele includes a mix of carbapenem market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa carbapenem market, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa carbapenem market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

MEA carbapenem market report size, by country, 2018-2030 (US$M)

Middle East & Africa Carbapenem Market Share, 2022 & 2030 (US$M)

MEA carbapenem market report size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more